Benitec Biopharma
Подписчиков: 0, рейтинг: 0
| Type | Biotechnology |
|---|---|
| Nasdaq: BNTC | |
| Industry | RNA interference |
| Founded | 1997 |
| Headquarters | Melbourne, VIC |
Key people |
Michael Graham (Founding Scientist & Head of Discovery) |
| Products | Gene silencing, Gene expression, RNA interference (ddRNAi) |
| Website | www.benitec.com |
Benitec Biopharma Ltd (ASX: BLT) is an Australian biotechnology company founded in 1997. It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.
The Commonwealth Scientific and Industrial Research Organisation (CSIRO) has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.
Research and development
Benitec Biopharma is researching ddRNAi in the following fields:
- Hepatitis B (under development with partner Biomics Biotechnologies))
- Oculopharyngeal muscular dystrophy (OPMD)